APPLICATION OF ANTI-IDIOTYPES TO AIDS AUTOANTIBODIES

最近的几项研究表明， 辅助性T细胞自身抗体与疾病的研究进展 人类免疫缺陷病毒(HIV)感染的进展。 这些研究的结果也表明，这些 自身抗体可能在获得性心脏病的发病中起作用 免疫缺陷综合征(艾滋病)。这项工作的主要目标是 建议开发临床有用的抗独特型(抗ID) 这些艾滋病相关的单抗(MoAbbs) 自身抗体。在第一阶段期间，抗ID将是 产生针对CD4+的细胞毒性自身抗体 从感染艾滋病毒的人身上分离出淋巴细胞。这些 将利用自身抗体和抗ID MoAbbs开发 检测HIV患者血清自身抗体水平的免疫分析方法 受感染的个体和对照人群。抗病毒检测 辅助T细胞自身抗体将与艾滋病相关 疾病参数和HIV感染的临床病程。 这些研究将持续到第二阶段，以确定 这些诊断试验在预测艾滋病进展中的作用 在感染艾滋病毒的人身上。此外，由于反身份证已经被 用来抑制自身免疫反应，开发的抗入侵检测系统 也可能在未来的治疗应用中发现抑制 自身抗体可能参与了艾滋病的发病机制。 总体而言，第一阶段和第二阶段研究的结果应会导致 新型诊断分析方法和治疗产品的开发 它可能会在未来的HIV管理中得到应用 在感染和治疗艾滋病相关疾病方面也是如此。

Several recent studies have demonstrated a correlation between the development of autoantibodies to helper T cells and disease progression in human immunodeficiency virus (HIV) infections. The results of these studies have also indicated that these autoantibodies may contribute to the pathogenesis of the acquired immune defeciency syndrome (AIDS). The main objective of this proposal is to develop clinically useful anti-idiotype (anti-Id) monoclonal antibodies (MoAbs) to these AIDS related autoantibodies. During the Phase I period, anti-Ids will be generated to cytotoxic autoantibodies specific for CD4+ lymphocytes isolated from individuals infected with HIV. These autoantibodies and anti-Id MoAbs will be utilized to develop immunoassays to measure serum autoantibody levels in HIV infected individuals and control populations. Detection of anti- helper T cell autoantibodies will be correlated with AIDs related disease parameters and the clinical course of HIV infections. These studies will be continued into the Phase II period to identify the role of these diagnostic assays in predicting AIDS progression in HIV infected individuals. In addition, as anti-Ids have been utilized to inhibit autoimmune responses, the developed anti-Ids may also find future therapeutic application in the suppression of autoantibodies which may be involved in AIDS pathogenesis. Overall, the results of the Phase I and II studies should lead to the development of novel diagnostic assays and therapeutic products which may find future application in the management of HIV infections and in the treatment of AIDS related disorders.